Economic Burden of Renal Cell Carcinoma—Part I: An Updated Review

Chun-Ru Chien, Daniel M. Geynisman, Bumyang Kim, Ying Xu and Ya-Chen Shih
Additional contact information
Chun-Ru Chien: China Medical University Hospital
Daniel M. Geynisman: Fox Chase Cancer Center, Temple Health
Bumyang Kim: University of Texas MD Anderson Cancer Center
Ying Xu: University of Texas MD Anderson Cancer Center

PharmacoEconomics, 2019, vol. 37, issue 3, No 2, 331 pages

Abstract: Abstract Background The economic burden of renal cell carcinoma (RCC) had been reported to be significant in a previous review published in 2011. Objective The objective of this study was to perform an updated review by synthesizing economic studies related to the treatment of RCC that have been published since the previous review. Methods We performed a literature search in PubMed, EMBASE, and the Cochrane Library, covering English-language studies published between June 2010 and August 2018. We categorized these articles by type of analyses [cost-effectiveness analysis (CEA), cost analysis, and cost of illness (COI)] and treatment setting (cancer status and treatment), discussed findings from these articles, and synthesized information from each article in summary tables. Results We identified 52 studies from 2317 abstracts/titles deemed relevant from the initial search, including 21 CEA, 23 cost analysis, and 8 COI studies. For localized RCC, costs were found to be positively associated with the aggressiveness of the local treatment. For metastatic RCC (mRCC), pazopanib was reported to be cost effective in the first-line setting. We also found that the economic burden of RCC has increased over time. Conclusion RCC continues to impose a substantial economic burden to the healthcare system. Despite the large number of treatment alternatives now available for advanced RCC, the cost effectiveness and budgetary impact of many new agents remain unknown and warrant greater attention in future research.

Date: 2019
References: View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
http://link.springer.com/10.1007/s40273-018-0746-y Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharme:v:37:y:2019:i:3:d:10.1007_s40273-018-0746-y

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40273

DOI: 10.1007/s40273-018-0746-y

Access Statistics for this article

PharmacoEconomics is currently edited by Timothy Wrightson and Christopher I. Carswell

More articles in PharmacoEconomics from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().